BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28528915)

  • 1. Sphingosine metabolism as a therapeutic target in cutaneous melanoma.
    Dany M
    Transl Res; 2017 Jul; 185():1-12. PubMed ID: 28528915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Insights into the Role of Sphingolipid Metabolism in Melanoma.
    Carrié L; Virazels M; Dufau C; Montfort A; Levade T; Ségui B; Andrieu-Abadie N
    Cells; 2020 Aug; 9(9):. PubMed ID: 32858889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acid Ceramidase in Melanoma: EXPRESSION, LOCALIZATION, AND EFFECTS OF PHARMACOLOGICAL INHIBITION.
    Realini N; Palese F; Pizzirani D; Pontis S; Basit A; Bach A; Ganesan A; Piomelli D
    J Biol Chem; 2016 Jan; 291(5):2422-34. PubMed ID: 26553872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of microRNAs in melanoma.
    Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
    Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipid/Ceramide Pathways and Autophagy in the Onset and Progression of Melanoma: Novel Therapeutic Targets and Opportunities.
    Lai M; La Rocca V; Amato R; Freer G; Pistello M
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingolipid metabolism and leukemia: a potential for novel therapeutic approaches.
    Burns TA; Luberto C
    Anticancer Agents Med Chem; 2011 Nov; 11(9):863-81. PubMed ID: 21707485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma genetics: the other side.
    Bis S; Tsao H
    Clin Dermatol; 2013; 31(2):148-55. PubMed ID: 23438378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.
    Camp ER; Patterson LD; Kester M; Voelkel-Johnson C
    Cancer Biol Ther; 2017 Sep; 18(9):640-650. PubMed ID: 28686076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic applications of bioactive sphingolipids in hematological malignancies.
    Ekiz HA; Baran Y
    Int J Cancer; 2010 Oct; 127(7):1497-506. PubMed ID: 20503271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine kinase-1--a potential therapeutic target in cancer.
    Cuvillier O
    Anticancer Drugs; 2007 Feb; 18(2):105-10. PubMed ID: 17159597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 in skin cancer: From a master player to a privileged target for prevention and therapy.
    Loureiro JB; Abrantes M; Oliveira PA; Saraiva L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188438. PubMed ID: 32980466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principles of bioactive lipid signalling: lessons from sphingolipids.
    Hannun YA; Obeid LM
    Nat Rev Mol Cell Biol; 2008 Feb; 9(2):139-50. PubMed ID: 18216770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.
    Shaw J; Costa-Pinheiro P; Patterson L; Drews K; Spiegel S; Kester M
    Adv Cancer Res; 2018; 140():327-366. PubMed ID: 30060815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
    Settleman J
    Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma.
    Zhang W; Zhao H; Chen J; Zhong X; Zeng W; Li Z; Zhou J; He Z; Tang S
    Life Sci; 2020 Jul; 253():117600. PubMed ID: 32234492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
    Selvam SP; Ogretmen B
    Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and sphingolipid storage disease therapy using novel synthetic analogs of sphingolipids.
    Gatt S; Dagan A
    Chem Phys Lipids; 2012 May; 165(4):462-74. PubMed ID: 22387097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
    Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
    Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
    Hiscutt EL; Hill DS; Martin S; Kerr R; Harbottle A; Birch-Machin M; Redfern CP; Fulda S; Armstrong JL; Lovat PE
    J Invest Dermatol; 2010 Sep; 130(9):2250-8. PubMed ID: 20520630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
    Rajakulendran T; Adam DN
    Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.